Uncategorized – 【國家衛生研究院】技轉及育成中心

Spot Light of Recent Invention(2023/06/01)

Latest news-English / 2023 年 5 月 29 日 2023 年 7 月 28 日

DBPR117: A Precision Medicine (mAb) Targeting RSPO3/Wnt-Mediated Tumorigenesis Abstract：Click here PowerPoint：Click here Neuroprotective Agent DBPR168 against Chemotherapy-Induced Peripheral Neuropathy Abstract：Click here PowerPoint：Click here DBPR376- New Luteinizing Hormone-Releasing Hormone Receptor (LHRHR)-Targeting Small Molecule Mertansine Conjugate for Cancer Treatment Abstract：Click here PowerPoint：Click here DBPR728: An Aurora kinase inhibitor for precision targeting of MYC-amplified solid tumors (A precision …

Spot Light of Recent Invention(2023/06/01) Read More »

Technology Available for Industry-Academia Collaboration or Technology Licensing. “DBPR807: A CXCR4-Targeted Antagonist” (2022/7/26)

Latest news-English, Uncategorized, Uncategorized, 技術-EN, 技術轉移招商en文章, 產學研發-EN, 產學研發徵求夥伴en文章 / 2022 年 7 月 26 日 2022 年 7 月 26 日

Technology Available for Industry-Academia Collaboration or Technology Licensing. “DBPR807: A CXCR4-Targeted Antagonist” Date: 2022.7.26 1. Title: NHRI technology, “DBPR807: A CXCR4-Targeted Antagonist” (abbreviated as “The Technology”) available for industry-academia collaboration or technology licensing. 2. Description: DBPR807 is a small molecule CXCR4 antagonist. DBPR807 can significantly suppress tumor growth of hepatocellular carcinoma via reducing angiogenesis, …

Technology Available for Industry-Academia Collaboration or Technology Licensing. “DBPR807: A CXCR4-Targeted Antagonist” (2022/7/26) Read More »